approval of Eliquis (ELL-eh-kwiss, apixaban) will intensify the marketing war among the NEW oral anticoagulants

The approval of Eliquis (ELL-eh-kwiss, apixaban) will intensify the marketing war among the NEW oral anticoagulants.

Eliquis will join Pradaxa (dabigatran) and Xarelto (rivaroxaban) as warfarin alternatives for preventing strokes in atrial fib.

Keep in mind how the new oral anticoagulants stack up for A fib.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote